

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPROVAL | | | | |
|--------------------------|-----------|--|--|--|
| OMB Number: | 3235-0104 | | | |
| Estimated average burden | | | | |
| nours per response | | | | |

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Response | es) | | | | | | | | | | | |
|--|--------------------|------------------------------|---|---|---|--|--|---|---|---|--|--|
| Ladin Brian D | | Statemen | Statement (Month/Day/Year) | | 3. Issuer Name and Ticker or Trading Symbol Nemus Bioscience, Inc. [NMUS] | | | | | | | |
| 2101 CEDAR SPR 1525 | (First) INGS RI | (Middle) D., SUITE | 12/10/2014 | | | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | to 5. If Amendment, Date Original Filed(Month/Day/Year) | | |
| DALLAS, TX 752 | (Street) | | | | | | Officer (give title Other (spe | | | | | |
| (City) | (State) | (Zip) | | Table I - Non-Derivative Securities Beneficially Owned | | | | | Owned | | | |
| 1. Title of Security (Instr. 4) | | | В | 2. Amount of Securities Beneficially Owned (Instr. 4) | | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | | | | |
| Common Stock | | | 29 | 299,589 (1) | | | I | See Footnote (2) (2) | | | | |
| Common Stock | | | 40 | 465,862 ⁽¹⁾ | | | I | See Footnote (3) (3) | | | | |
| Common Stock | | | 32 | 329,228 (1) | | I | See Footnote (4) (4) | | | | | |
| Reminder: Report on a | Person unless | ns who respo the form dis | ond to the c splays a cui | collection rrently val | of info | ormatio IB cont | n contained in t | | · | | | |
| 1. Title of Derivative Security (Instr. 4) | | 2. Date Exer and Expirati | 2. Date Exercisable and Expiration Date Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivativ Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: Direct | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | | | |
| | _ | | Date Exercisable | Expiration Date | | | t or Number of | Security | (D) or Indirect (I) (Instr. 5) | | | |
| | | | | | | | | | | | | |

Reporting Owners

| | Relationships | | | |
|---|---------------|--------------|---------|-------|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other |
| Ladin Brian D 2101 CEDAR SPRINGS RD. SUITE 1525 DALLAS, TX 75201 | | X | | |

Signatures

| /s/Brian D. Ladin | 12/17/2014 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Mr. Ladin disclaims beneficial ownership of any securities reported herein except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of such shares for purposes of Section 16 or for any other purpose.
- (2) Represents shares of common stock, no par value (the "Common Stock") of Nemus Bioscience, Inc. directly beneficially owned by Southern Investments I LLC.
- (3) Represents shares of Common Stock directly beneficially owned by TC Global Management LLC.
- (4) Represents shares of Common Stock directly beneficially owned by BRL TX- Family LP.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.